<DOC>
	<DOCNO>NCT01014806</DOCNO>
	<brief_summary>- To assess tolerability safety single injection Influenza VLP Vaccine administer intramuscularly ( IM ) 15 µg 60 µg HA per strain . - To assess immunogenicity Influenza VLP Vaccine administer 15 µg 60 µg HA per strain measure hemagglutination inhibition ( HAI ) antibody titer component viral strain [ A/Brisbane/59/2007 ( H1N1 ) ; A/Brisbane/10/2007 ( H3N2 ) B/Brisbane/60/2008 ] .</brief_summary>
	<brief_title>Evaluate Safety Immunogenicity Seasonal Influenza Virus-Like Particle ( VLP ) Vaccine Older Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male female &gt; 60 year age time vaccination . 2 . Informed consent must obtain subject prior beginning study specific procedure indicate understand purpose study willing adhere procedure describe protocol . 3 . Available telephone . 4 . Free obvious health problem chronic illness ( i.e. , recent exacerbation acute episode chronic illness last 3 month ) establish medical history , review system , clinical examination enter study . This include mental condition would interfere subject selfassessment . Subjects preexist chronic disease allow participate disease stable . Stable disease define new onset exacerbation preexist chronic disease 3 month prior study vaccine injection . 1 . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede administration study vaccine , plan use study period . 2 . Receipt license influenza vaccine investigational influenza vaccine within 6 month prior enrollment study expect receipt vaccination final immune response blood collection . 3 . History hypersensitivity component inactivate influenza vaccine , include egg egg product , gelatin , arginine . 4 . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior administration study vaccine . The use inhale nasal steroid permit . 5 . Any medically diagnose suspect immunodeficient condition base medical history physical examination . 6 . Administration immunoglobulins and/or blood product within three month precede administration study vaccine study . 7 . Acute disease time enrollment . Acute disease define presence moderate severe illness without fever &gt; 100.5F . 8 . Acute clinically significant pulmonary , include asthma , cardiovascular , hepatic renal functional abnormality determine physical examination laboratory screen test . 9 . Major congenital defect may increase risk influenza complication . 10 . History neurological disorder seizure ( exception febrile seizure childhood ) relate underlie immune disease disorder , limited : multiple sclerosis , lupus , GuillainBarre syndrome . Other neurological disorder clinically mild stable medication , mild Parkinson 's disease , exclude . 11 . Any condition opinion investigator would interfere evaluation vaccine interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>